公开(公告)号：US20180344660A1

公开(公告)日：2018-12-06

申请号：US15757899

申请日：2016-09-08

申请人： GW Pharma Limited

发明人： Philip Robson ,  Geoffrey Guy ,  Stephen Wright ,  Emma Cheetham ,  Dominic Schiller

IPC分类号： A61K31/05 ,  A61K31/496 ,  A61K31/5513 ,  A61K31/554 ,  A61K31/519 ,  A61K31/40 ,  A61P25/18

CPC分类号： A61K31/05 ,  A61K31/40 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/554 ,  A61P25/18 ,  A61K2300/00

摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

公开(公告)号：US10653641B2

公开(公告)日：2020-05-19

申请号：US15757899

申请日：2016-09-08

申请人： GW Pharma Limited

发明人： Philip Robson ,  Geoffrey Guy ,  Stephen Wright ,  Emma Cheetham ,  Dominic Schiller

IPC分类号： A61K31/05 ,  A61P25/18 ,  A61K31/496 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/40 ,  A61K31/519 ,  A61K31/554

摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

公开(公告)号：US20210059959A1

公开(公告)日：2021-03-04

申请号：US16845204

申请日：2020-04-10

申请人： GW Pharma Limited

发明人： Philip ROBSON ,  Geoffrey Guy ,  Stephen Wright ,  Emma Cheetham ,  Dominic Schiller

IPC分类号： A61K31/05 ,  A61K31/496 ,  A61K31/40 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/554 ,  A61P25/18 ,  A61K31/551

摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

公开(公告)号：US20150359756A1

公开(公告)日：2015-12-17

申请号：US14741829

申请日：2015-06-17

申请人： GW Pharma Limited

发明人： Geoffrey Guy ,  Stephen Wright ,  Alice Mead ,  Emma Cheetham ,  Orrin Devinsky ,  Dominic Schiller

IPC分类号： A61K31/05 ,  A61K47/44 ,  A61K47/10 ,  A61K47/26 ,  A61K31/19 ,  A61K31/53 ,  A61K31/4015 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/27 ,  A61K31/197 ,  A61K31/165 ,  A61K31/5517 ,  A61K31/36 ,  A61K31/35 ,  A61K31/496 ,  A61K31/423 ,  A61K36/185

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K2300/00

摘要： The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

摘要翻译： 本公开涉及使用大麻二醇（CBD）来治疗不发作的发作。 特别地，本公开涉及使用CBD来减少患有病因的患者的不发作癫痫发作，其包括：Lennox-Gastaut综合征; 结节性硬化综合征; Dravet综合征 Doose综合征 CDKL5; Dup15q; Jeavons综合征 肌阵挛性癫痫; 神经元样细胞脂褐素（NCL）和脑异常。 本公开还涉及CBD与一种或多种抗癫痫药（AED）的组合的用途。